Oncology News | pharmaphorum

News

Seagen posts breast cancer win ahead of Pfizer takeover

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a

News

Abcuro raises $155m for KLRG1 drug trial

Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

FDA starts speedy review of Servier's Tibsovo in MDS

Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a p

News

Gilead taps Tentarix for cancer, inflammation projects

Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

Seagen posts breast cancer win ahead of Pfizer takeover

Abcuro raises $155m for KLRG1 drug trial

Keytruda backed for 'basket' of new cancers via NHS

FDA starts speedy review of Servier's Tibsovo in MDS

Gilead taps Tentarix for cancer, inflammation projects

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks